TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06680232: Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B

Sponsor: Precision BioSciences, Inc. · Phase: PHASE1 · Area: INFECTIOUS_VACCINE · Target Enrollment: 45 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$659,736

Rescue Site Savings

+$439,824

Unlock Full NCT06680232 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06680232 Rescue Dossier →